TearScience Secured up to $70M in Funding from HealthCare Royalty Partners

TearScience, Inc., a Morrisville, North Carolina-based medical device company that focuses on the worldwide dry eye market, secured up to $70m in funding from HealthCare Royalty Partners.

The company intends to use the capital to implement its commercialization efforts.

Led by Tim Willis, President & CEO, TearScience has developed and launched TearScience a system for evaporative dry eye, which includes the LipiView® Ocular Surface Interferometer and the LipiFlow® Thermal Pulsation System. LipiView measures the absolute thickness of the lipid layer of a dry eye patient’s tear film while LipiFlow treats the root cause of evaporative dry eye disease by unblocking obstructed Meibomian glands during an in-office procedure.



Join the discussion